文献速递眼底病与葡萄膜炎

玻璃体腔注射抗血管内皮生长因子药物后发生孔源性视网膜脱离

Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor.
PubMed 文献 · Ophthalmology · 2019-04-28

该单中心回顾性连续病例复习纳入2014年10月1日至2017年10月1日因新生血管性年龄相关性黄斑变性或视网膜静脉阻塞接受雷珠单抗、贝伐珠单抗或阿柏西普注射的患者,共12 718例患者180 671次注射,24例在注射后3个月内发生孔源性视网膜脱离(RRD),发生率为每7532次注射1例(0.013%)及每530例患者1例(0.19%);24例中15例(62.5%)视网膜裂孔位于注射象限1.5钟点范围内(P<0.0001),诊断RRD时9例(37.5%)黄斑在位,最终随访平均16.3个月时黄斑在位组视力平均下降1.0行,黄斑脱离组下降6.8行(P=0.027)。

要点

  • RRD发生率为每7532次注射1例(0.013%)及每530例患者1例(0.19%)。
  • 24例RRD中15例(62.5%)裂孔位于注射象限1.5钟点范围内(P<0.0001)。
  • 最终随访平均16.3个月时,黄斑在位组视力平均下降1.0行,黄斑脱离组下降6.8行(P=0.027)。

核心结论

  • 玻璃体腔注射后视网膜脱离不常见,发生率约为每7500次注射1例。
  • 诊断RRD时的黄斑状态显著影响视力结局。

研究设计与样本

  • 单中心、回顾性、连续病例复习。
  • 纳入2014年10月1日至2017年10月1日因新生血管性年龄相关性黄斑变性或视网膜静脉阻塞接受雷珠单抗、贝伐珠单抗或阿柏西普注射的所有患者。
  • 眼数与注射次数由计费代码确定,RRD患者由计费记录确定并经病历复习确认。
  • 共纳入12 718例患者180 671次玻璃体腔注射。

主要发现

  • 24例患者在注射后3个月内发生RRD,发生率为每7532次注射1例(0.013%)及每530例患者1例(0.19%)。
  • 注射后RRD风险与诊断(P=0.54)、医生经验(P=0.23)、注射部位(P=0.41)、卡尺使用(P=0.75)或31G与30G针头使用(P=0.18)均无关联。
  • 24例中15例(62.5%)视网膜裂孔位于注射象限1.5钟点范围内(P<0.0001)。
  • 诊断RRD时9例(37.5%)黄斑在位。
  • RRD修复干预包括玻璃体切除术(PPV;15例)、巩膜扣带联合PPV(4例)、充气性视网膜固定术(3例)及单纯激光或冷冻治疗(2例)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the rate, risk factors, and outcomes of rhegmatogenous retinal detachment (RRD) after intravitreal injection of anti-vascular endothelial growth factor medications. DESIGN: Single-center, retrospective, consecutive review. PARTICIPANTS: All patients receiving ranibizumab, bevacizumab, or aflibercept for neovascular age-related macular degeneration or retinal vein occlusion between October 1, 2014, and October 1, 2017. METHODS: The total number of eyes and injections were determined from billing codes. Rhegmatogenous retinal detachment patients were determined from billing records and confirmed with chart review. MAIN OUTCOME MEASURES: Rate of retinal detachment and visual acuity outcomes. RESULTS: A total of 180 671 intravitreal injections in 12 718 unique patients were included. An RRD occurred in 24 patients within 3 months after injection, giving a rate of 1 RRD per 7532 intravitreal injections (0.013%) and 1 RRD per 530 patients (0.19%). No association was found between RRD risk after injection and diagnosis (P = 0.54), physician experience (P = 0.23), injection site (P = 0.41), caliper use (P = 0.75), or 31- versus 30-gauge needle use (P = 0.18). A retinal tear was found located in the quadrant of the injection site (within 1.5 clock hours of the injection) in 15 of 24 patients (62.5%; P < 0.0001). At the time of RRD diagnosis, the macula was attached in 9 patients (37.5%). Interventions for RRD repair included pars plana vitrectomy (PPV; 15 patients), combined scleral buckle and PPV (4 patients), pneumatic retinopexy (3 patients), and laser or cryotherapy alone (2 patients). Single-surgery success rate was 54.2%, with 54.5% of recurrent detachments caused by proliferative vitreoretinopathy. Average loss from visual acuity recorded at the visit before diagnosis of RRD was 1.0 line for macula-on detachments versus 6.8 lines for macula-off detachments (P = 0.027) at final follow-up (average, 16.3 months). CONCLUSIONS: Retinal detachment after intravitreal injection is uncommon, with a rate of approximately 1 in 7500 injections. Macular status at the time of RRD diagnosis significantly affects visual outcomes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Storey PP, Pancholy M, Wibbelsman TD, et al. Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. Ophthalmology. 2019. PMID: 31042567. doi:10.1016/j.ophtha.2019.04.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。